Main Article Content

Dr. M. Lenin
Dr. J. Sivakumar
Dr. Kuzhandi velu
Dr. S. SelvaKumar
Dr. Ramesh Ramasammy


Gestational diabetes mellitus, C-peptide, Insulin Resistance, HOMA-IR


AIM: The current study aimed to investigate the relationship between C-peptide and other surrogate markers in patients with gestational diabetes mellitus in the Puducherry population.

Methodology: Five milliliters of venous blood (without anticoagulant) were drawn from pregnant women with and without GDM. The fasting glucose level was determined using the glucose oxidase method (GOD-POD), and the fasting lipid profile (total cholesterol, TAG-C, HDL-C, and LDL-C) was measured using an auto analyzer and the IFCC Approved method. Insulin resistance markers such as c-peptide and HOMA-IR were calculated. Insulin levels were calculated. Insulin was measured using chemiluminescence technology in a Roche auto analyzer (cobas e411).

Result: C-peptide had a strong relationship with insulin and HOMA-IR. In GDM, C-peptide has a higher sensitivity (88%) and specificity (89%). Conclusion: This study found a link between C-peptide levels and insulin levels in GDM patients in Puducherry, and C-peptide levels are predictive of GDM.

Conclusion: C-peptide can also be used to determine glycemic control status. C-peptide levels are used to predict gestational diabetes mellitus.

Abstract 205 | pdf Downloads 87


1. Virjee S, Robinson S, Johnston DG. Screening for diabetes in pregnancy. J R Soc Med. 2001 Oct;94(10):502–9.
2. Gupta K, Parmar M, Dubey S. Incidence of Gestational Diabetes Mellitus in Pregnant women from Rural Background Attending Antenatal Care Clinic. Int J Med Res Rev [Internet].2015Mar31[cited2017Oct10];3(02).Availablefrom:http://medresearch.in/inde x.php/IJMRR/article/view/229
3. Vani K. Alterations in lipid profile in gestational diabetes mellitus (GDM) and type 2 DM women during pregnancy. Int J Med Res Rev [Internet]. 2015 Sep 30 [cited 2017 May26];3(08). Available from: http://medresearch.in/index.php/IJMRR/article/view/351
4. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005 Mar 1;115(3):485–91.
5. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160–4.
6. Cerf ME. Beta Cell Dysfunction and Insulin Resistance. Front Endocrinol [Internet]. 2013Mar27;4.Availablefrom: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608918
7. Chailurkit L, Jongjaroenprasert W, Chanprasertyothin S, Ongphiphadhanakul B. Insulin and C-peptide levels, pancreatic beta cell function, and insulin resistance across glucose tolerance status in Thais. J Clin Lab Anal. 2007;21(2):85–90.
8. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes. 2010 Jul;59(7):1765–70.
9. Halliday HL, Reid MM, Hadden DR. C-peptide levels in transient neonatal diabetes. Diabet Med J Br Diabet Assoc. 1986 Jan;3(1):80–1
10. Viikari J, Rönnemaa T, Koskinen P. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients. Ann Clin Res. 1987;19(3):178–82
11. Kampmann U, Madsen LR, Skajaa GO, Iversen DS, Moeller N, Ovesen P. Gestational diabetes: A clinical update. World J Diabetes. 2015 Jul 25;6(8):1065–72
12. Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017 Jun;8(3):475–87.
13. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013 Jul;30(7):803–17.
14. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management.
15. Front Endocrinol [Internet]. 2017 Jan 24;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256065/
16. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010 May 15;1(2):36–47.
17. Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications. Curr Diabetes Rev. 2014 Jan;10(1):2–42.
18. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations. Vasc Health Risk Manag. 2012;8:463–72.
19. Leibowitz G, Kaiser N, Cerasi E. β‐ Cell failure in type 2 diabetes. J Diabetes Investig. 2011 Apr 7;2(2):82–91.
20. Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Medica. 2013 Oct 15;23(3):266–80.
21. Marrif HI, Al-Sunousi SI. Pancreatic β Cell Mass Death. Front Pharmacol [Internet]. 2016Apr6;7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821858/
22. AMERICAN DIABETES ASSOCIATION. Diagnosis and Classification of Diabetes Mellitus. 31.
23. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, et al. Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. J Clin Endocrinol Metab. 2013 May 1;98(5):2100
24. Radaelli T, Farrell KA, Huston-Presley L, Amini SB, Kirwan JP, McIntyre HD, et al. Estimates of Insulin Sensitivity Using Glucose and C-Peptide From the Hyperglycemia and Adverse Pregnancy Outcome Glucose Tolerance Test. Diabetes Care. 2010 Mar;33(3):490–4.
25. Shaat N, Ekelund M, Lernmark A, Ivarsson S, Ramelius A, Perfekt R, et al. Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus. Diabetologia. 2004 Jun 1;47:878–84.
26. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013 Jan 22;12:21